Cargando…

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients

A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin®) + 5-fluorouracil (5-FU) ± folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bensmaïne, M A, Marty, M, Gramont, A de, Brienza, S, Lévi, F, Ducreux, M, François, E, Gamelin, E, Bleiberg, H, Cvitkovic, E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364084/ https://www.ncbi.nlm.nih.gov/pubmed/11506488 http://dx.doi.org/10.1054/bjoc.2001.1953

Ejemplares similares

Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma.
por: Zaniboni, A., et al.
Publicado: (1988)

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma
por: Correale, P, et al.
Publicado: (2004)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

Fluorouracil (5-FU)-induced Cardiomyopathy
por: Thalambedu, Nishanth, et al.
Publicado: (2019)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
por: De Angelis, Paula M, et al.
Publicado: (2006)

A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer†
por: Chitapanarux, I, et al.
Publicado: (2011)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals
por: Ahmad, Maqsood, et al.
Publicado: (2012)

A unique presentation of 5-fluorouracil (5-FU) induced cerebral encephalopathy
por: Naik, Shailendra S, et al.
Publicado: (2020)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
por: Folprecht, Gunnar, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.
por: Goldberg, J. A., et al.
Publicado: (1988)

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
por: Conroy, T, et al.
Publicado: (2008)

Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines
por: Suetsugu, Tomonari, et al.
Publicado: (2021)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity
por: Fischel, J L, et al.
Publicado: (2002)

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.
por: Fleming, R. A., et al.
Publicado: (1992)

Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells
por: Kim, Eun-Ji, et al.
Publicado: (2018)

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation
por: Fu, Jinbo, et al.
Publicado: (2019)

Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.
por: Onodera, H., et al.
Publicado: (1990)

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
por: Gonçalves-Ribeiro, Samuel, et al.
Publicado: (2016)

Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
por: Sun, Xianjun, et al.
Publicado: (2020)

Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
por: Negrei, Carolina, et al.
Publicado: (2016)

Eukaryotic translation initiation factor 3 subunit G (EIF3G) resensitized HCT116/5-Fu to 5-fluorouracil (5-Fu) via inhibition of MRP and MDR1
por: Yang, Chenggang, et al.
Publicado: (2018)

5-FU toxicity and nutritional deficiencies.
por: Stenram, U.
Publicado: (1993)

Transcriptomic and network pharmacology approaches revealed possible mechanisms underlying the 5-fluorouracil (5-FU)-sensitizing effect of Xuan-Fu-Hua decoction treatment on liver cancer cells
por: Luo, Wen-Zhao, et al.
Publicado: (2022)

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
por: Garufi, C, et al.
Publicado: (2003)

Efficacy of Fractional Carbon Dioxide Laser (FCO(2)) with Intralesional 5-Fluorouracil (5-FU) in the Treatment of Keloids
por: Alhamzawi, Nabeel Kadhim
Publicado: (2021)

Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells
por: Mori, Ryutaro, et al.
Publicado: (2012)

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
por: Dolat, Marine, et al.
Publicado: (2020)

The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
por: Zafar, Amna, et al.
Publicado: (2022)

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
por: Singhal, Ruchi, et al.
Publicado: (2023)

Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer
por: Jonker, D., et al.
Publicado: (2006)

Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer
por: Steber, Cole, et al.
Publicado: (2021)

Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil
por: Han, Jung Ho, et al.
Publicado: (2021)

The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay
por: Gunnlaugsson, Adalsteinn, et al.
Publicado: (2009)

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
por: Rao, S, et al.
Publicado: (2005)

Initial experience with topical fluorouracil (5-FU) for treatment of anal intraepithelial neoplasia (AIN) in HIV-positive patients
por: Snyder, Sean M, et al.
Publicado: (2010)

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
por: Wagner, A D, et al.
Publicado: (2009)

Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
por: Schlumberger, M., et al.
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_bi8qvgdgs3frjrmtv75cbiqidk